RS-0139
Integrin receptor-expressing solid tumors
Phase 1Active
Key Facts
About RS Research
RS Research is a clinical-stage biotech leveraging its proprietary Sagitta® targeted delivery platform to develop next-generation polymer-drug conjugates for oncology. The company has a lead candidate, RS-0139 (docetaxel conjugate), currently in Phase I trials, with initial data accepted for presentation at ASCO 2025. Founded by award-winning innovators and recognized as a translational success story, RS Research aims to create safer, more effective chemotherapies and theranostics by selectively delivering payloads to tumors.
View full company profile